Kumaraguru Raja
Stock Analyst at Brookline Capital
(0.27)
# 4,383
Out of 5,182 analysts
17
Total ratings
20%
Success rate
-21.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INTS Intensity Therapeutics | Upgrades: Buy | $75 | $5.17 | +1,350.68% | 1 | Aug 12, 2025 | |
| PALI Palisade Bio | Maintains: Buy | $16 | $1.95 | +720.51% | 2 | May 13, 2025 | |
| QNCX Quince Therapeutics | Initiates: Buy | $90 | $1.23 | +7,217.07% | 1 | Dec 18, 2024 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $3.53 | +126.63% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $26.27 | +280.66% | 2 | May 30, 2024 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $0.26 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $3,750 | $1.56 | +240,284.62% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $0.72 | +1,985.36% | 1 | Jun 29, 2023 | |
| ATYR aTyr Pharma | Reinstates: Buy | $9 | $0.79 | +1,034.07% | 1 | Mar 6, 2023 | |
| RAIN Rain Enhancement Technologies Holdco | Reinstates: Buy | $21 | $2.26 | +827.73% | 1 | Jan 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $90 | $54.48 | +65.20% | 1 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $290 → $310 | $2.29 | +13,437.12% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33,600 | $1.26 | +2,666,566.67% | 1 | Sep 21, 2021 |
Intensity Therapeutics
Aug 12, 2025
Upgrades: Buy
Price Target: $75
Current: $5.17
Upside: +1,350.68%
Palisade Bio
May 13, 2025
Maintains: Buy
Price Target: $16
Current: $1.95
Upside: +720.51%
Quince Therapeutics
Dec 18, 2024
Initiates: Buy
Price Target: $90
Current: $1.23
Upside: +7,217.07%
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $3.53
Upside: +126.63%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $26.27
Upside: +280.66%
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.26
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $3,750
Current: $1.56
Upside: +240,284.62%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $0.72
Upside: +1,985.36%
aTyr Pharma
Mar 6, 2023
Reinstates: Buy
Price Target: $9
Current: $0.79
Upside: +1,034.07%
Rain Enhancement Technologies Holdco
Jan 31, 2023
Reinstates: Buy
Price Target: $21
Current: $2.26
Upside: +827.73%
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $54.48
Upside: +65.20%
May 18, 2022
Maintains: Buy
Price Target: $290 → $310
Current: $2.29
Upside: +13,437.12%
Sep 21, 2021
Initiates: Buy
Price Target: $33,600
Current: $1.26
Upside: +2,666,566.67%